About Potassium channel subfamily K member 18
Potassium channel subfamily K member 18 (KCNK18) is a protein
from Homo sapiens identified by UniProt accession
Q7Z418, 384 residues long.
MolForge cross-references it against 0 known binders and
122 disease associations.
Target properties
| Protein name | Potassium channel subfamily K member 18 |
| UniProt accession | Q7Z418 |
| Gene | KCNK18 |
| Organism | Homo sapiens |
| Length | 384 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (122)
Diseases linked to this target (Open Targets).
- delirium · score 0.56
- Agitation · score 0.55
- coronary artery disease · score 0.55
- pain · score 0.54
- ischemia reperfusion injury · score 0.54
- kidney failure · score 0.53
- acute respiratory distress syndrome · score 0.52
- post operative nausea and vomiting · score 0.50
- hypotension · score 0.50
- COVID-19 · score 0.48
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q7Z418-F1 | alphafold | PREDICTED | 69.78 | — |
Amino-acid sequence (384 residues)
MEVSGHPQAR RCCPEALGKL FPGLCFLCFL VTYALVGAVV FSAIEDGQVL VAADDGEFEK FLEELCRILN CSETVVEDRK QDLQGHLQKV KPQWFNRTTH WSFLSSLFFC CTVFSTVGYG YIYPVTRLGK YLCMLYALFG IPLMFLVLTD TGDILATILS TSYNRFRKFP FFTRPLLSKW CPKSLFKKKP DPKPADEAVP QIIISAEELP GPKLGTCPSR PSCSMELFER SHALEKQNTL QLPPQAMERS NSCPELVLGR LSYSIISNLD EVGQQVERLD IPLPIIALIV FAYISCAAAI LPFWETQLDF ENAFYFCFVT LTTIGFGDTV LEHPNFFLFF SIYIIVGMEI VFIAFKLVQN RLIDIYKNVM LFFAKGKFYH LVKK
Explore Potassium channel subfamily K member 18 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets